An ongoing clinical trial evaluating CDX as a single agent in metastatic AR+, ER-/PR- breast cancers (NCT00468715/TBCRC011) has demonstrated some efficacy with a clinical benefit rate of 19% [24]. Here, ESR1 is linked to breast cancer.